Definitions
Sorry, no definitions found. Check out and contribute to the discussion of this word!
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word microplasmin.
Examples
-
The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent in stroke.
-
THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that its lead product microplasmin, which is in Phase III trials for the treatment of vitreomacular adhesion, is progressing according to schedule.
Gaea Times (by Simple Thoughts) Breaking News and incisive views 24/7 Thrombogenics Nv 2009
-
The Company's lead product ocriplasmin (microplasmin) has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA).
unknown title 2011
-
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint (p = 0.003).
-
The primary endpoint of both trials is the non-surgical resolution of focal vitreomacular adhesion one month after a single injection of microplasmin.
-
These trials are designed to evaluate 125μg of microplasmin versus placebo in the intravitreal treatment of patients with symptomatic focal vitreomacular adhesion (VMA).
-
The fact that microplasmin resolved VMA without surgery in approximately 30% of patients is a clinically important development.
-
A Per Protocol analysis of the microplasmin treated patient population showed that 30. 7% achieved resolution of their VMA
-
The results of the first trial, TG-MV-006, confirmed that it had met its primary endpoint with 27. 7% of microplasmin treated patients achieving resolution of their VMA compared to
-
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint (p = 0.003).
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.